Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
March 06, 2024 09:00 ET
|
BIOXYTRAN, INC.
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
February 21, 2024 08:00 ET
|
BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
October 24, 2023 08:45 ET
|
BIOXYTRAN, INC.
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Bioxytran Interview at the Emerging Growth Conference
October 04, 2023 09:00 ET
|
BIOXYTRAN, INC.
Thursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage...
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
September 14, 2023 09:41 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
August 24, 2023 09:00 ET
|
BIOXYTRAN, INC.
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
August 08, 2023 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
July 31, 2023 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations
June 27, 2023 07:00 ET
|
BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in...
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
June 12, 2023 09:00 ET
|
BIOXYTRAN, INC.
- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company...